Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Qiagen ( (QGEN) ) is now available.
QIAGEN disclosed a managers’ transaction involving Roland Sackers, a member of the managing board, under European market abuse regulations. The notification relates to equity-based compensation and highlights the company’s adherence to transparency requirements for insider dealings.
The event concerns the release of 2,107 performance stock units granted in 2016 and the net settlement into 1,116 common shares after withholding a portion to cover taxes and transaction costs. While the volumes are described as not quantifiable in aggregate, the move underscores ongoing alignment of executive incentives with shareholder value through stock-based remuneration.
The most recent analyst rating on (QGEN) stock is a Buy with a $58.00 price target. To see the full list of analyst forecasts on Qiagen stock, see the QGEN Stock Forecast page.
More about Qiagen
QIAGEN N.V. is a Netherlands-based life sciences company specializing in sample and assay technologies for molecular diagnostics, applied testing, academic research, and pharmaceutical development. Its shares are listed on multiple European exchanges as well as the NYSE and Swiss markets, reflecting a broad international investor base.
Average Trading Volume: 2,173,009
Technical Sentiment Signal: Strong Buy
Current Market Cap: $10.1B
See more insights into QGEN stock on TipRanks’ Stock Analysis page.